Bayer Takes Over Saridon Trademark Lawsuit From Roche
This article was originally published in PharmAsia News
Executive Summary
China's Supreme Court recently accepted Southwest Pharmaceutical's appeal to have a retrial of its trademark violation case, the firm's final chance to keep its Saridon (sanlietong) trademark after two failed attempts. The lawsuit between Southwest Pharmaceutical and Roche has dragged for more than a decade; now a new player joins in the fray. Roche has transferred Saridon's production and trademark to Bayer, thus passing the hot potato to the new owner. Bayer declines to comment on the lawsuit retrial, but points out that Saridon plays an important role in its developing China's generic drug market. Analysts believe that the corporation will not sit idly by and do nothing about the Sanlietong issue. (Click here for more - Chinese Language)
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.